Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GH Research ( (GHRS) ) just unveiled an update.
On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational TRD therapy GH001, clearing the drug for clinical investigation in the United States and enabling U.S. patient enrollment. The company plans to align with the FDA on a global Phase 3 program modeled on its Phase 2b trial, which previously met its primary endpoint with a strong MADRS score reduction, high rapid-remission rates, short treatment sessions, and a favorable safety profile, potentially strengthening GH Research’s competitive position in next-generation depression treatments and supporting the integration of GH001 into existing interventional psychiatry practices if later-stage data are positive.
The most recent analyst rating on (GHRS) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held down primarily by weak operating fundamentals (no revenue, expanding losses, and sustained cash burn). Technical indicators also point to weak momentum with price below key moving averages and a negative MACD. Offsetting factors are a low-debt, equity-supported balance sheet that reduces solvency risk, but valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for treatment-resistant depression (TRD). Its lead product candidate, GH001, is an inhaled formulation designed to offer ultra-rapid and durable antidepressant effects, positioning the company within the fast-growing interventional psychiatry market for difficult-to-treat mood disorders.
Average Trading Volume: 309,095
Technical Sentiment Signal: Buy
Current Market Cap: $821.3M
Learn more about GHRS stock on TipRanks’ Stock Analysis page.